Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Biotechnology

Healthcare
$6.30 -4.15%

-$0.41 today

Market cap
$192.17M
Beta
0.78
P/E (TTM)
-1.7
EPS (TTM)
-$5.65
52W Low $5.60High $15.57

Volume 0.17M

Average 0.26M

RNAC Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Cartesian Therapeutics, Inc.NASDAQ: RNAC

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity remains negative

Q1 FY2026 total equity was -$148.12M, compared with -$21.79M a year earlier.

Context

  • Total equity amounted to 51.4% of total assets at the end of Q1 FY2026, up 46.0 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -579.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$148.12M-17.3% QoQ
Last fiscal yearDec 2025
-$126.24M-1755.9% YoY
Year agoMar 2025
-$21.79M-579.8% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-579.8%——
1 year-1755.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
(126.24M) USD
Year-over-year change
-1755.9%

Total Equity vs competitors

How RNAC compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -579.8% is the lowest of 10, against a peer median of +32.5%.
  • Total equity amounts to 51.4% of total assets for RNAC, versus a peer median of 68.4%.
RNAC Competitors
Total Equity for RNAC and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NAUTNautilus Biotechnology, Inc.Mar 2026$144.42M USD-25.7%-20.7%81.2%
EPRXEupraxia Pharmaceuticals Inc.Mar 2026$136.64M USD+405.4%+102.0%93.7%
AARDAardvark Therapeutics, Inc. Common StockMar 2026$86.99M USD-42.3%—88.2%
AVTXAvalo Therapeutics, Inc.Mar 2026$68.32M USD-44.3%—68.4%
OBIOOrchestra BioMed Holdings, Inc.Mar 2026$50.97M USD+202.3%+6.5%50.6%
MDWDMediWound Ltd.Mar 2026$41.42M USD+32.5%+58.7%51.8%
FENCFennec Pharmaceuticals Inc.Mar 2026$37.68M USD+740.7%—52.5%
NTHINeonc Technologies Holdings, Inc.Mar 2026-$13.23M USD-37.5%—397.3%
IVAInventiva S.A.Dec 2025-€29.04M EUR+72.8%—11.7%
RNACCartesian Therapeutics, Inc.Mar 2026-$148.12M USD-579.8%—51.4%
Peer median (excluding RNAC) —+32.5%+32.6%68.4%

Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents114.06M106.44M76.91M212.61M125.14M
Short-term Investments14M28.16M000
Net Receivables9.91M9.86M8.85M872K1.12M
Inventory00000
Other Current Assets03.68M4.97M3.14M3.02M
Total Current Assets144.44M148.14M90.73M216.63M129.28M
Property, Plant & Equipment (Net)11.97M14.41M12.18M15.45M17.79M
Goodwill0048.16M48.16M48.16M
Intangible Assets00150.6M150.6M0
Long-term Investments2M2M2M2M1.74M
Tax Assets00000
Other Non-current Assets1.47M1.34M1.38M2.19M99.45M
Total Non-current Assets15.44M17.75M214.32M218.4M167.14M
Total Assets159.88M165.89M305.05M435.02M296.41M
Account Payables224K316K3.15M288K1.29M
Short-term Debt5.96M8.48M004.15M
Tax Payables601K0000
Deferred Revenue53.88M593K2.31M00
Other Current Liabilities0056.19M7.76M5.51M
Total Current Liabilities72.25M25.08M68.21M22.98M14.94M
Long-term Debt19.67M17.79M000
Deferred Tax Liabilities00322.08M16.14M6.95M
Deferred Revenue (Non-current)11.42M03.54M00
Other Non-current Liabilities25.42M19.14M342.62M391.58M392.24M
Total Non-current Liabilities65.11M46.98M677.03M418.85M407.71M
Total Liabilities137.36M72.06M745.23M441.83M422.65M
Common Stock12K15K16K3K3K
Retained Earnings(430.32M)(394.94M)(614.65M)(692.07M)(822.37M)
Accumulated OCI(4.57M)(4.56M)(4.6M)(4.62M)(4.58M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity22.52M93.83M(440.18M)(6.8M)(126.24M)
Total Debt35.28M37.93M10.96M13.98M12.68M
Net Debt(78.78M)(68.51M)(65.96M)(198.63M)(112.46M)

Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Intrinsic Alpha fair value

Locked

Current Price

$6.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.